Canadian Journal of Physiology and Pharmacology · 1986 · 22 citations · 0 references
PharmacyPharmaceutical AnalysisPharmacologyCardiovascular PharmacotherapyChromatographic AnalysisClinical PharmacologyBioanalytical Method ValidationChromatographic Analysis Of PharmaceuticalsClinical AnalysisAntihypertensive Drug TherapyAntihypertensive PharmacologyAntihypertensive TreatmentHigh-performance Liquid ChromatographyHigh-performance Liquid Chromatography AnalysisNifedipine TherapySerum Biomarkers
Techniques are described for the analysis of nifedipine and three of its metabolites; dehydronifedipine (I), dehydronifedipinic acid (II), and dehydronifedipinolactone (III) in human serum and urine. The analytes are extracted at pH 9 or 3 with ethyl acetate and chromatographed on a C8 reverse-phase column. Recoveries from spiked control serum and urine ranged from 70 to 95% depending on the polarity of the analyte. The coefficient of variation ranged from 10 to 15% (nifedipine, I, and III at 50-200 ng/mL) and 15-20% (II at 200-2000 ng/mL). Accuracy was always within the limits of precision. The metabolism of nifedipine in a group of hypertensive patients receiving long-term nifedipine therapy was compared with that reported for acute administration. Serum nifedipine levels were comparable in both cases, but contrary to previous reports, dehydronifedipine was consistently found in significant amounts. Serum levels of II were considerably elevated but III was not detected either in serum or in urine. Thus, prolonged nifedipine therapy in conjunction with other antihypertensive medications appears to be associated with significant alterations in the metabolism of nifedipine compared with acute administration.